Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT04761705 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

SUSPENDED

Status

70

Enrollment

INDUSTRY

Sponsor class

Stopped Awaiting transition to Part 2

Conditions

Ocular Hypertension
Open Angle Glaucoma

Interventions

DRUG: JV-GL1
DRUG: Latanoprost 0.005% Ophthalmic Solution

Sponsor

JeniVision, Inc.